| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | -0.048 | 0.8 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.053 | 0.8 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.054 | 0.8 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.014 | 0.8 |